Mycobacterium Infections
13
6
6
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.7%
1 terminated out of 13 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Training Protocol on the Natural History of Tuberculosis
Study of Mycobacterial Infections
Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt)
Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Gene Expression Profiles in Spinal Tuberculosis.
M. Avium WGS During Mav-PD Treatment
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
A Single Ascending Dose Study of BTZ043
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
Rapid Identification of Mycobacteria in Acid-fast Bacilli Smear-positive Respiratory Specimens
Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections